Publications in collaboration with researchers from Yale School of Medicine (11)

2022

  1. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 3

2021

  1. Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL-8

    Journal of Pathology, Vol. 255, Núm. 2, pp. 190-201

  2. IL8, neutrophils, and NETs in a collusion against cancer immunity and immunotherapy

    Clinical Cancer Research, Vol. 27, Núm. 9, pp. 2383-2393

2020

  1. CXCR1 and CXCR2 Chemokine Receptor Agonists Produced by Tumors Induce Neutrophil Extracellular Traps that Interfere with Immune Cytotoxicity

    Immunity, Vol. 52, Núm. 5, pp. 856-871.e8

2019

  1. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma

    Nature Medicine, Vol. 25, Núm. 3, pp. 470-476

  2. Today's special on the anticancer menu: Immunomodulation by antifolates

    Clinical Cancer Research, Vol. 25, Núm. 23, pp. 6890-6892

2018

  1. Liquid Biopsy: From Basic Research to Clinical Practice

    Advances in Clinical Chemistry (Academic Press Inc.), pp. 73-119

2017

  1. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and crosspriming

    Cancer Research, Vol. 76, Núm. 20, pp. 5994-6005

2015

  1. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 112, Núm. 24, pp. 7551-7556

  2. Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-/-IL2Rγnull immunodeficient mice

    Cancer Research, Vol. 75, Núm. 17, pp. 3466-3478